DALLAS–(BUSINESS WIRE)–EnLiSense CCM, a medical health wearables technology company that non-invasively measures inflammatory biomarkers with sweat, announced today that it has received an investment from the Crohn’s & Colitis Foundation’s IBD Ventures program to develop EnLiSense CCM’s IBD AWARE product. IBD AWARE is an inflammation tracker targeting key biomarkers associated with inflammatory bowel disease (IBD).

The IBD AWARE device and sensor rests on a patient’s skin sampling nano-liters of passive sweat and will continuously measure and report biomarkers such as C-Reactive Protein (CRP), Calprotectin, Interleukin-6 (IL6), Tumor Necrosis Factor alpha (TNF-α), Interleukin-1 beta (IL1-β), Cortisol and other biomarkers. Additional details about the IBD AWARE platform and how it works can be found at https://www.ibdwearable.com.